Zoetis Inc.: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-05-22
Other years: 2025 vs 2024 · 2024 vs 2023
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Zoetis expanded its risk disclosures by adding five new risk factors in 2026, including three related to convertible senior notes financing obligations and two addressing emerging operational risks around AI/machine learning and evolving trade policy frameworks. The company removed one tariff-focused risk from 2025, which was consolidated into a broader trade policy risk addressing tariffs, sanctions, and trade restrictions. Nine existing risks underwent substantive modifications, with notable updates to disclosures on intellectual property challenges, regulatory compliance, supply chain dependencies, and sustainability commitments.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

5
New Risks
1
Removed
9
Modified
37
Unchanged
🟢 New in Current Filing

Changes in trade policies, including the imposition of tariffs, sanctions, and other trade restrictions, may adversely affect our business.

The U.S. and other countries in which our products are sourced or sold, or we or our customers do business, may from time to time modify existing or impose new quotas, duties (including antidumping or countervailing duties), tariffs, economic sanctions, export controls, or other…

Read full text

The U.S. and other countries in which our products are sourced or sold, or we or our customers do business, may from time to time modify existing or impose new quotas, duties (including antidumping or countervailing duties), tariffs, economic sanctions, export controls, or other restrictions in a manner that adversely affects us. Such measures could limit our ability to register our products, source materials, sell products, or conduct our business in certain markets. While the scope and duration of any existing trade policies remain uncertain, any new tariffs imposed by the U.S. or other governments on our products or the active pharmaceutical ingredients or other components thereof could negatively impact our financial condition and results of operations. Current or future tariffs or other restrictive trade measures may raise the costs of raw materials, components or finished goods, which may adversely impact both our product offerings and our operational expenses. Our manufacturers, suppliers and distribution channels may also experience supply chain disruptions as a result of increased costs and uncertainty. Duties are assessed based on import value. Each jurisdiction applies its own rules and procedures for import valuation, increasing the complexity and risk of errors. While we maintain procedures to ensure compliance, there is no guarantee these will prevent all errors, and regulatory changes may heighten this risk. Additional tariffs and other trade restrictions could result in a negative perception and/or an increased cost of goods and higher prices which may reduce demand for products and services, or extended sales cycles as customers assess the impact of evolving trade policies on their operations and face increased costs or decreased revenue. Additionally, a number of our customers, particularly U.S.-based livestock producers, benefit from free trade agreements, the loss of which could impact their operating results and spending power. Tariff and other trade-related cost pressures and supply chain disruptions may lead to reputational harm if we are unable to deliver products or services on expected timelines or if any price increases are poorly received by customers or business partners. In addition, retaliatory trade policies or anti-U.S. sentiment in certain regions whether driven by trade tensions, political disagreements or regulatory concerns may make customers, governments and investors more hesitant to engage with, purchase from or invest in U.S. companies. This may lead to increased preference for local competitors, changes to government procurement policies or heightened regulatory scrutiny, which may result in heightened operational risks and difficulties for us in attracting and retaining non-U.S. customers, suppliers, partners and investors.

🟢 New in Current Filing We use machine learning and AI in various business operations, and inability to successfully monitor and manage its use could result in operational, competitive or reputational harm, regulatory enforcement, and legal liability. 🔒
🟢 New in Current Filing We may not have the ability to raise the funds necessary to settle conversions of our convertible senior notes in cash, or to repurchase the convertible senior notes upon a fundamental change, and our existing debt contains, and future debt may contain, limitations on our ability to pay cash upon conversion or repurchase of the convertible senior notes. 🔒
🟢 New in Current Filing The conditional conversion feature of our convertible senior notes, if triggered, may adversely affect our financial condition and operating results. 🔒
🟢 New in Current Filing Conversion of our convertible senior notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock. 🔒
🔴 No Match in Current Filing Modification of foreign trade policy by the U.S. or other countries or the imposition of tariffs on imported goods may harm our business. 🔒
🟡 Modified If our intellectual property rights are challenged or circumvented, competitors may be able to take advantage of our research and development efforts. 🔒
🟡 Modified Our business is subject to substantial regulation. 🔒
🟡 Modified We rely on third parties to provide us with products, materials and services, and are subject to increased labor and material costs and potential disruptions in supply. 🔒
🟡 Modified Our aspirations, goals and disclosures related to sustainability matters expose us to numerous risks, including risks to our reputation. 🔒
🟡 Modified Our results of operations are dependent upon the success of our top-selling products. 🔒
🟡 Modified Our operations and reputation may be impacted if we do not comply with complex and continually evolving laws and regulations regarding data privacy information and the use of AI. 🔒
🟡 Modified Our products are subject to unanticipated safety, quality or efficacy concerns. 🔒
🟡 Modified We depend on sophisticated information technology and infrastructure. 🔒
🟡 Modified We may be unable to adequately protect our information technology systems from cyberattacks, ransomware attacks, phishing attempts, social engineering schemes and other technology enabled threats, breaches of security, data loss or misappropriation of data, which could result in the disclosure of sensitive, personal, confidential or proprietary information, damage our reputation, and subject us to significant financial and legal exposure. 🔒
14 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →